Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Identifieur interne : 000068 ( PubMed/Corpus ); précédent : 000067; suivant : 000069

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Auteurs : Tatsuya Atsumi ; Kazuhiko Yamamoto ; Tsutomu Takeuchi ; Hisashi Yamanaka ; Naoki Ishiguro ; Yoshiya Tanaka ; Katsumi Eguchi ; Akira Watanabe ; Hideki Origasa ; Shinsuke Yasuda ; Yuji Yamanishi ; Yasuhiko Kita ; Tsukasa Matsubara ; Masahiro Iwamoto ; Toshiharu Shoji ; Toshiyuki Okada ; Désirée Van Der Heijde ; Nobuyuki Miyasaka ; Takao Koike

Source :

RBID : pubmed:26139005

English descriptors

Abstract

To evaluate efficacy and safety of combination therapy using certolizumab pegol (CZP) and methotrexate (MTX) as first-line treatment for MTX-naive, early rheumatoid arthritis (RA) with poor prognostic factors, compared with MTX alone.

DOI: 10.1136/annrheumdis-2015-207511
PubMed: 26139005

Links to Exploration step

pubmed:26139005

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.</title>
<author>
<name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name>
<affiliation>
<nlm:affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yamamoto, Kazuhiko" sort="Yamamoto, Kazuhiko" uniqKey="Yamamoto K" first="Kazuhiko" last="Yamamoto">Kazuhiko Yamamoto</name>
<affiliation>
<nlm:affiliation>The University of Tokyo, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Takeuchi, Tsutomu" sort="Takeuchi, Tsutomu" uniqKey="Takeuchi T" first="Tsutomu" last="Takeuchi">Tsutomu Takeuchi</name>
<affiliation>
<nlm:affiliation>Keio University School of Medicine, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yamanaka, Hisashi" sort="Yamanaka, Hisashi" uniqKey="Yamanaka H" first="Hisashi" last="Yamanaka">Hisashi Yamanaka</name>
<affiliation>
<nlm:affiliation>Tokyo Women's Medical University, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ishiguro, Naoki" sort="Ishiguro, Naoki" uniqKey="Ishiguro N" first="Naoki" last="Ishiguro">Naoki Ishiguro</name>
<affiliation>
<nlm:affiliation>Faculty of Medicine, Nagoya University Graduate School, Nagoya, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name>
<affiliation>
<nlm:affiliation>University of Occupational and Environmental Health, Kitakyushu, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Eguchi, Katsumi" sort="Eguchi, Katsumi" uniqKey="Eguchi K" first="Katsumi" last="Eguchi">Katsumi Eguchi</name>
<affiliation>
<nlm:affiliation>Sasebo Chuo Hospital, Nagasaki, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Watanabe, Akira" sort="Watanabe, Akira" uniqKey="Watanabe A" first="Akira" last="Watanabe">Akira Watanabe</name>
<affiliation>
<nlm:affiliation>Tohoku University, Sendai, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Origasa, Hideki" sort="Origasa, Hideki" uniqKey="Origasa H" first="Hideki" last="Origasa">Hideki Origasa</name>
<affiliation>
<nlm:affiliation>University of Toyama School of Medicine, Toyama, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yasuda, Shinsuke" sort="Yasuda, Shinsuke" uniqKey="Yasuda S" first="Shinsuke" last="Yasuda">Shinsuke Yasuda</name>
<affiliation>
<nlm:affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yamanishi, Yuji" sort="Yamanishi, Yuji" uniqKey="Yamanishi Y" first="Yuji" last="Yamanishi">Yuji Yamanishi</name>
<affiliation>
<nlm:affiliation>Hiroshima Rheumatology Clinic, Hiroshima, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Kita, Yasuhiko" sort="Kita, Yasuhiko" uniqKey="Kita Y" first="Yasuhiko" last="Kita">Yasuhiko Kita</name>
<affiliation>
<nlm:affiliation>Yokohama Rosai Hospital, Yokohama, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Matsubara, Tsukasa" sort="Matsubara, Tsukasa" uniqKey="Matsubara T" first="Tsukasa" last="Matsubara">Tsukasa Matsubara</name>
<affiliation>
<nlm:affiliation>Matsubara Mayflower Hospital, Kato, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Iwamoto, Masahiro" sort="Iwamoto, Masahiro" uniqKey="Iwamoto M" first="Masahiro" last="Iwamoto">Masahiro Iwamoto</name>
<affiliation>
<nlm:affiliation>Jichi Medical University, Tochigi, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Shoji, Toshiharu" sort="Shoji, Toshiharu" uniqKey="Shoji T" first="Toshiharu" last="Shoji">Toshiharu Shoji</name>
<affiliation>
<nlm:affiliation>UCB Pharma, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Okada, Toshiyuki" sort="Okada, Toshiyuki" uniqKey="Okada T" first="Toshiyuki" last="Okada">Toshiyuki Okada</name>
<affiliation>
<nlm:affiliation>Astellas Pharma Inc., Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name>
<affiliation>
<nlm:affiliation>Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Miyasaka, Nobuyuki" sort="Miyasaka, Nobuyuki" uniqKey="Miyasaka N" first="Nobuyuki" last="Miyasaka">Nobuyuki Miyasaka</name>
<affiliation>
<nlm:affiliation>Tokyo Medical and Dental University, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Koike, Takao" sort="Koike, Takao" uniqKey="Koike T" first="Takao" last="Koike">Takao Koike</name>
<affiliation>
<nlm:affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan NTT Sapporo Medical Centre, Sapporo, Japan.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26139005</idno>
<idno type="pmid">26139005</idno>
<idno type="doi">10.1136/annrheumdis-2015-207511</idno>
<idno type="wicri:Area/PubMed/Corpus">000068</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.</title>
<author>
<name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name>
<affiliation>
<nlm:affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yamamoto, Kazuhiko" sort="Yamamoto, Kazuhiko" uniqKey="Yamamoto K" first="Kazuhiko" last="Yamamoto">Kazuhiko Yamamoto</name>
<affiliation>
<nlm:affiliation>The University of Tokyo, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Takeuchi, Tsutomu" sort="Takeuchi, Tsutomu" uniqKey="Takeuchi T" first="Tsutomu" last="Takeuchi">Tsutomu Takeuchi</name>
<affiliation>
<nlm:affiliation>Keio University School of Medicine, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yamanaka, Hisashi" sort="Yamanaka, Hisashi" uniqKey="Yamanaka H" first="Hisashi" last="Yamanaka">Hisashi Yamanaka</name>
<affiliation>
<nlm:affiliation>Tokyo Women's Medical University, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ishiguro, Naoki" sort="Ishiguro, Naoki" uniqKey="Ishiguro N" first="Naoki" last="Ishiguro">Naoki Ishiguro</name>
<affiliation>
<nlm:affiliation>Faculty of Medicine, Nagoya University Graduate School, Nagoya, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name>
<affiliation>
<nlm:affiliation>University of Occupational and Environmental Health, Kitakyushu, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Eguchi, Katsumi" sort="Eguchi, Katsumi" uniqKey="Eguchi K" first="Katsumi" last="Eguchi">Katsumi Eguchi</name>
<affiliation>
<nlm:affiliation>Sasebo Chuo Hospital, Nagasaki, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Watanabe, Akira" sort="Watanabe, Akira" uniqKey="Watanabe A" first="Akira" last="Watanabe">Akira Watanabe</name>
<affiliation>
<nlm:affiliation>Tohoku University, Sendai, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Origasa, Hideki" sort="Origasa, Hideki" uniqKey="Origasa H" first="Hideki" last="Origasa">Hideki Origasa</name>
<affiliation>
<nlm:affiliation>University of Toyama School of Medicine, Toyama, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yasuda, Shinsuke" sort="Yasuda, Shinsuke" uniqKey="Yasuda S" first="Shinsuke" last="Yasuda">Shinsuke Yasuda</name>
<affiliation>
<nlm:affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yamanishi, Yuji" sort="Yamanishi, Yuji" uniqKey="Yamanishi Y" first="Yuji" last="Yamanishi">Yuji Yamanishi</name>
<affiliation>
<nlm:affiliation>Hiroshima Rheumatology Clinic, Hiroshima, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Kita, Yasuhiko" sort="Kita, Yasuhiko" uniqKey="Kita Y" first="Yasuhiko" last="Kita">Yasuhiko Kita</name>
<affiliation>
<nlm:affiliation>Yokohama Rosai Hospital, Yokohama, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Matsubara, Tsukasa" sort="Matsubara, Tsukasa" uniqKey="Matsubara T" first="Tsukasa" last="Matsubara">Tsukasa Matsubara</name>
<affiliation>
<nlm:affiliation>Matsubara Mayflower Hospital, Kato, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Iwamoto, Masahiro" sort="Iwamoto, Masahiro" uniqKey="Iwamoto M" first="Masahiro" last="Iwamoto">Masahiro Iwamoto</name>
<affiliation>
<nlm:affiliation>Jichi Medical University, Tochigi, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Shoji, Toshiharu" sort="Shoji, Toshiharu" uniqKey="Shoji T" first="Toshiharu" last="Shoji">Toshiharu Shoji</name>
<affiliation>
<nlm:affiliation>UCB Pharma, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Okada, Toshiyuki" sort="Okada, Toshiyuki" uniqKey="Okada T" first="Toshiyuki" last="Okada">Toshiyuki Okada</name>
<affiliation>
<nlm:affiliation>Astellas Pharma Inc., Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name>
<affiliation>
<nlm:affiliation>Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Miyasaka, Nobuyuki" sort="Miyasaka, Nobuyuki" uniqKey="Miyasaka N" first="Nobuyuki" last="Miyasaka">Nobuyuki Miyasaka</name>
<affiliation>
<nlm:affiliation>Tokyo Medical and Dental University, Tokyo, Japan.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Koike, Takao" sort="Koike, Takao" uniqKey="Koike T" first="Takao" last="Koike">Takao Koike</name>
<affiliation>
<nlm:affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan NTT Sapporo Medical Centre, Sapporo, Japan.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Annals of the rheumatic diseases</title>
<idno type="e-ISSN">1468-2060</idno>
<imprint>
<date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Antibodies (blood)</term>
<term>Antirheumatic Agents (adverse effects)</term>
<term>Antirheumatic Agents (therapeutic use)</term>
<term>Arthritis, Rheumatoid (blood)</term>
<term>Arthritis, Rheumatoid (drug therapy)</term>
<term>Arthritis, Rheumatoid (radiography)</term>
<term>Blood Sedimentation</term>
<term>Certolizumab Pegol (adverse effects)</term>
<term>Certolizumab Pegol (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination (adverse effects)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Methotrexate (adverse effects)</term>
<term>Methotrexate (therapeutic use)</term>
<term>Middle Aged</term>
<term>Peptides, Cyclic (immunology)</term>
<term>Prognosis</term>
<term>Remission Induction</term>
<term>Rheumatoid Factor (blood)</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antirheumatic Agents</term>
<term>Certolizumab Pegol</term>
<term>Methotrexate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antibodies</term>
<term>Rheumatoid Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Peptides, Cyclic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antirheumatic Agents</term>
<term>Certolizumab Pegol</term>
<term>Methotrexate</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Arthritis, Rheumatoid</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Arthritis, Rheumatoid</term>
</keywords>
<keywords scheme="MESH" qualifier="radiography" xml:lang="en">
<term>Arthritis, Rheumatoid</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Blood Sedimentation</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Remission Induction</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">To evaluate efficacy and safety of combination therapy using certolizumab pegol (CZP) and methotrexate (MTX) as first-line treatment for MTX-naive, early rheumatoid arthritis (RA) with poor prognostic factors, compared with MTX alone.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26139005</PMID>
<DateCreated>
<Year>2015</Year>
<Month>12</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>2016</Year>
<Month>04</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2016</Year>
<Month>01</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1468-2060</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>75</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2016</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Annals of the rheumatic diseases</Title>
<ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.</ArticleTitle>
<Pagination>
<MedlinePgn>75-83</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2015-207511</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate efficacy and safety of combination therapy using certolizumab pegol (CZP) and methotrexate (MTX) as first-line treatment for MTX-naive, early rheumatoid arthritis (RA) with poor prognostic factors, compared with MTX alone.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">MTX-naive, early RA patients with ≤12 months persistent disease, high anti-cyclic citrullinated peptide, and either rheumatoid factor positive and/or presence of bone erosions were enrolled in this multicentre, double-blind, randomised placebo (PBO)-controlled study. Patients were randomised 1:1 to CZP+MTX or PBO+MTX for 52 weeks. Primary endpoint was inhibition of radiographic progression (change from baseline in modified Total Sharp Score (mTSS CFB)) at week 52. Secondary endpoints were mTSS CFB at week 24, and clinical remission rates at weeks 24 and 52.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">316 patients randomised to CZP+MTX (n=159) or PBO+MTX (n=157) had comparable baseline characteristics reflecting features of early RA (mean disease duration: 4.0 vs 4.3 months; Disease Activity Score 28-joint assessment (DAS28)) (erythrocyte sedimentation rate (ESR)): 5.4 vs 5.5; mTSS: 5.2 vs 6.0). CZP+MTX group showed significantly greater inhibition of radiographic progression relative to PBO+MTX at week 52 (mTSS CFB=0.36 vs 1.58; p<0.001) and week 24 (mTSS CFB=0.26 vs 0.86; p=0.003). Clinical remission rates (Simple Disease Activity Index, Boolean and DAS28 (ESR)) of the CZP+MTX group were significantly higher compared with those of the PBO+MTX group, at weeks 24 and 52. Safety results in both groups were similar, with no new safety signals observed with addition of CZP to MTX.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In MTX-naive early RA patients with poor prognostic factors, CZP+MTX significantly inhibited structural damage and reduced RA signs and symptoms, demonstrating the efficacy of CZP in these patients.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">(NCT01451203).</AbstractText>
<CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Atsumi</LastName>
<ForeName>Tatsuya</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamamoto</LastName>
<ForeName>Kazuhiko</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>The University of Tokyo, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takeuchi</LastName>
<ForeName>Tsutomu</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Keio University School of Medicine, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamanaka</LastName>
<ForeName>Hisashi</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Tokyo Women's Medical University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ishiguro</LastName>
<ForeName>Naoki</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Medicine, Nagoya University Graduate School, Nagoya, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tanaka</LastName>
<ForeName>Yoshiya</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eguchi</LastName>
<ForeName>Katsumi</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Sasebo Chuo Hospital, Nagasaki, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Watanabe</LastName>
<ForeName>Akira</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Tohoku University, Sendai, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Origasa</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>University of Toyama School of Medicine, Toyama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yasuda</LastName>
<ForeName>Shinsuke</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yamanishi</LastName>
<ForeName>Yuji</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Hiroshima Rheumatology Clinic, Hiroshima, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Kita</LastName>
<ForeName>Yasuhiko</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Yokohama Rosai Hospital, Yokohama, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Matsubara</LastName>
<ForeName>Tsukasa</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Matsubara Mayflower Hospital, Kato, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Iwamoto</LastName>
<ForeName>Masahiro</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Jichi Medical University, Tochigi, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Shoji</LastName>
<ForeName>Toshiharu</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>UCB Pharma, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Okada</LastName>
<ForeName>Toshiyuki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Astellas Pharma Inc., Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>van der Heijde</LastName>
<ForeName>Désirée</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-5781-158X</Identifier>
<AffiliationInfo>
<Affiliation>Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miyasaka</LastName>
<ForeName>Nobuyuki</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Koike</LastName>
<ForeName>Takao</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Hokkaido University Graduate School of Medicine, Sapporo, Japan NTT Sapporo Medical Centre, Sapporo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT01451203</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Ann Rheum Dis</MedlineTA>
<NlmUniqueID>0372355</NlmUniqueID>
<ISSNLinking>0003-4967</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C487763">cyclic citrullinated peptide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9009-79-4</RegistryNumber>
<NameOfSubstance UI="D012217">Rheumatoid Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>UMD07X179E</RegistryNumber>
<NameOfSubstance UI="D000068582">Certolizumab Pegol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
<NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Care Res (Hoboken). 2012 May;64(5):625-39</RefSource>
<PMID Version="1">22473917</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2010 Sep;62(9):2569-81</RefSource>
<PMID Version="1">20872595</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2014 Mar;73(3):536-43</RefSource>
<PMID Version="1">23316080</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2014 Mar;73(3):492-509</RefSource>
<PMID Version="1">24161836</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2015 Jun;74(6):1037-44</RefSource>
<PMID Version="1">24550168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mod Rheumatol. 2014 Sep;24(5):715-24</RefSource>
<PMID Version="1">24313916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mod Rheumatol. 2014 Jul;24(4):552-60</RefSource>
<PMID Version="1">24981319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Rheumatol. 2000 Jan;27(1):261-3</RefSource>
<PMID Version="1">10648051</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Rheumatology (Oxford). 2000 Jun;39 Suppl 1:9-16</RefSource>
<PMID Version="1">11001374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2000 Nov 30;343(22):1586-93</RefSource>
<PMID Version="1">11096165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2003 Feb;62(2):120-6</RefSource>
<PMID Version="1">12525380</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2003 May;62(5):427-30</RefSource>
<PMID Version="1">12695154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S154-7</RefSource>
<PMID Version="1">14969068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2004 Mar;50(3):709-15</RefSource>
<PMID Version="1">15022309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Rheumatology (Oxford). 2011 Oct;50(10):1908-15</RefSource>
<PMID Version="1">21752873</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Rheumatology (Oxford). 2004 Jul;43(7):906-14</RefSource>
<PMID Version="1">15113999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 1989 May 13;1(8646):1036-8</RefSource>
<PMID Version="1">2565997</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2004 Nov;50(11):3432-43</RefSource>
<PMID Version="1">15529377</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Res Ther. 2005;7(5):R949-58</RefSource>
<PMID Version="1">16207336</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2006 Jan;54(1):26-37</RefSource>
<PMID Version="1">16385520</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2006 Apr;65(4):453-8</RefSource>
<PMID Version="1">16176994</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Intern Med. 2007 Jun 5;146(11):797-808</RefSource>
<PMID Version="1">17548411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Mod Rheumatol. 2007;17(6):451-8</RefSource>
<PMID Version="1">18084695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2008 Feb;67(2):212-7</RefSource>
<PMID Version="1">17526555</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arthritis Rheum. 2008 Nov;58(11):3319-29</RefSource>
<PMID Version="1">18975346</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2009 Jun;68(6):797-804</RefSource>
<PMID Version="1">19015207</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2010 Jun;69(6):964-75</RefSource>
<PMID Version="1">20444750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2010 Jun;69(6):976-86</RefSource>
<PMID Version="1">20447957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2010 Jul;69(7):1286-91</RefSource>
<PMID Version="1">20360136</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2010 Sep;69(9):1580-8</RefSource>
<PMID Version="1">20699241</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Rheum Dis. 2013 Jan;72(1):64-71</RefSource>
<PMID Version="1">22562973</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000906">Antibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001172">Arthritis, Rheumatoid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001799">Blood Sedimentation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000068582">Certolizumab Pegol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010456">Peptides, Cyclic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012217">Rheumatoid Factor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4717398</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Anti-TNF</Keyword>
<Keyword MajorTopicYN="N">Disease Activity</Keyword>
<Keyword MajorTopicYN="N">Early Rheumatoid Arthritis</Keyword>
<Keyword MajorTopicYN="N">Inflammation</Keyword>
<Keyword MajorTopicYN="N">Rheumatoid Arthritis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>2</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>6</Month>
<Day>6</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint">
<Year>2015</Year>
<Month>7</Month>
<Day>2</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>4</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26139005</ArticleId>
<ArticleId IdType="pii">annrheumdis-2015-207511</ArticleId>
<ArticleId IdType="doi">10.1136/annrheumdis-2015-207511</ArticleId>
<ArticleId IdType="pmc">PMC4717398</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000068 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000068 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:26139005
   |texte=   The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:26139005" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a OperaV1 

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020